Free Trial

Wall Street Zen Downgrades Henry Schein (NASDAQ:HSIC) to Hold

Henry Schein logo with Medical background

Key Points

  • Henry Schein has been downgraded from a "buy" rating to a "hold" rating by investment analysts at Wall Street Zen, reflecting a shift in sentiment towards the stock.
  • The company's stock is currently trading at $63.17 after experiencing a decline of 2.2%, with average analyst ratings summarizing to a consensus target price of $76.67.
  • During its most recent earnings report, Henry Schein missed analysts' earnings expectations with reported EPS of $1.10, compared to the consensus estimate of $1.19.
  • Five stocks to consider instead of Henry Schein.

Henry Schein (NASDAQ:HSIC - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued on Saturday.

A number of other research analysts also recently issued reports on the company. Weiss Ratings reissued a "hold (c)" rating on shares of Henry Schein in a research note on Wednesday. JPMorgan Chase & Co. decreased their target price on Henry Schein from $80.00 to $76.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. Baird R W lowered Henry Schein from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 14th. Robert W. Baird reaffirmed a "neutral" rating and issued a $72.00 target price (down from $82.00) on shares of Henry Schein in a research report on Monday, July 14th. Finally, Barrington Research reaffirmed an "outperform" rating and issued a $78.00 target price on shares of Henry Schein in a research report on Tuesday, September 23rd. Five investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $76.67.

Read Our Latest Research Report on Henry Schein

Henry Schein Stock Down 2.2%

Shares of NASDAQ:HSIC opened at $63.17 on Friday. The company has a market capitalization of $7.66 billion, a price-to-earnings ratio of 20.38, a P/E/G ratio of 2.13 and a beta of 0.81. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78. The business's 50-day moving average is $67.48 and its 200-day moving average is $68.81. Henry Schein has a 1 year low of $60.56 and a 1 year high of $82.49.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.19 by ($0.09). The business had revenue of $3.24 billion during the quarter, compared to analyst estimates of $3.22 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The firm's revenue for the quarter was up 3.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.23 earnings per share. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. Equities research analysts predict that Henry Schein will post 4.74 earnings per share for the current year.

Institutional Trading of Henry Schein

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HSIC. CYBER HORNET ETFs LLC bought a new position in shares of Henry Schein in the second quarter valued at approximately $25,000. MUFG Securities EMEA plc bought a new position in shares of Henry Schein in the second quarter valued at approximately $27,000. Rakuten Securities Inc. bought a new position in shares of Henry Schein in the first quarter valued at approximately $34,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Henry Schein in the second quarter valued at approximately $43,000. Finally, Steph & Co. bought a new position in shares of Henry Schein in the second quarter valued at approximately $44,000. 96.62% of the stock is owned by institutional investors.

Henry Schein Company Profile

(Get Free Report)

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Read More

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Henry Schein Right Now?

Before you consider Henry Schein, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.

While Henry Schein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.